-
公开(公告)号：EP3108255B1
公开(公告)日：2020-08-12
申请号：EP15704806.7
申请日：2015-02-18
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Centre National de la Recherche Scientifique (C.N.R.S.) , Université Grenoble Alpes , Commissariat à l'Energie Atomique et aux Energies Alternatives , Université de Bourgogne
发明人： BELAID-CHOUCAIR, Zakia , HERMINE, Olivier , GARRIDO-FLEURY, Carmen , COCHET, Claude , FILHOL-COCHET, Odile , SEIGNEURIC, Renaud
IPC分类号： G01N33/574 , G01N33/50
-
2.发明公开METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY THE NRP-1/OBR COMPLEX SIGNALING PATHWAY 审中-公开方法和药物组合物治疗由NRP-1 / OBR KOMPLEXSIGNALWEG介导的疾病
公开(公告)号：EP3108255A1
公开(公告)日：2016-12-28
申请号：EP15704806.7
申请日：2015-02-18
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Centre National de la Recherche Scientifique (C.N.R.S.) , Université Grenoble Alpes , Commissariat à l'Energie Atomique et aux Energies Alternatives , Université de Bourgogne
发明人： BELAID-CHOUCAIR, Zakia , HERMINE, Olivier , GARRIDO-FLEURY, Carmen , COCHET, Claude , FILHOL-COCHET, Odile , SEIGNEURIC, Renaud
IPC分类号： G01N33/574 , G01N33/50
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
摘要翻译： 本发明涉及用于治疗疾病由NRP-1 / OBR复杂信号传导途径介导的疾病的方法和药物组合物。 特别地，本发明涉及一种用于治疗选自下组在有需要的受试者的癌症，肥胖症和肥胖症相关疾病，厌食，自身免疫性疾病和感染性疾病由......组成，其包括施用与治疗有效量的本发明的疾病 的NRP-1 / OBR信号传导途径的拮抗剂。
-
3.发明公开
公开(公告)号：EP3256148A1
公开(公告)日：2017-12-20
申请号：EP16704599.6
申请日：2016-02-11
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université Paris Descartes , Centre National de la Recherche Scientifique (C.N.R.S.) , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Universite de Nantes , Université d'Angers , Centre Hospitalier Universitaire d'Angers
发明人： CRUZ-MOURA, Ivan , BARDET, Valérie , DUSSIOT, Michaël , TROVATI MACIEL, Thiago , TAMBURINI, Jérôme , IFRAH, Norbert , HERMINE, Olivier
IPC分类号： A61K38/18 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/74 , A61K39/3955 , C07K16/22 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57426 , G01N2333/475 , G01N2333/51 , G01N2800/22 , G01N2800/52
摘要： The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.
-
4.发明公开COMPOSITION COMPRISING A COMBINATION OF DNA METHYLATION INHIBITOR AND A VITAMIN D RECEPTOR AGONIST FOR THE TREATMENT OF DRUG RESISTANT CANCER OR FOR THE PREVENTION OF TUMOR RELAPSE 审中-公开有用于癌症药物用于预防肿瘤复发耐于治疗DNA甲基化抑制剂和维生素D受体激动剂的组合组成
公开(公告)号：EP3157533A1
公开(公告)日：2017-04-26
申请号：EP15729204.6
申请日：2015-06-19
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Centre National de la Recherche Scientifique (C.N.R.S.) , Université Paris Descartes , Fondation Imagine , Université Paris Diderot - Paris 7 , Universite Paris-Sud , Assistance Publique-Hôpitaux de Paris (APHP)
发明人： CRUZ-MOURA, Ivan , HERMINE, Olivier , PAUBELLE, Etienne , DUSSIOT, Michaël , TROVATI MACIEL, Thiago , ZYLBERSZTEJN, Florence
IPC分类号： A61K31/593 , A61K31/341 , A61K31/53
CPC分类号： A61K31/706 , A61K31/341 , A61K31/53 , A61K31/593 , A61K45/06 , A61K2300/00
摘要： The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
摘要翻译： 本发明涉及和/或预防肿瘤复发中的患者用于在耐药性癌症的治疗中同时或依次使用（ⅰ）的DNA甲基化抑制剂，和（ii）维生素D受体激动剂的组合， 从癌症。 因此，本发明涉及式（I）的DNA甲基化抑制剂，和组合（ⅱ）维生素D受体激动剂，在从患有癌症的患者增加，恢复或增强从患有癌症的患者的灵敏度对化疗药物 ，
-
公开(公告)号：EP3353196A1
公开(公告)日：2018-08-01
申请号：EP16775121.3
申请日：2016-09-21
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Descartes , Centre National de la Recherche Scientifique (CNRS) , Université de Bourgogne , CNAM-CONSERVATOIRE NATIONAL DES ARTS ET METIERS
发明人： BELAID-CHOUCAIR, Zakia , HERMINE, Olivier , MONTES, Matthieu , GARRIDO-FLEURY, Carmen , SEIGNEURIC, Renaud , MARCION, Guillaume
IPC分类号： C07K14/575 , C07K14/72 , C07K14/705
CPC分类号： C07K14/475 , A61K38/1866 , A61K39/3955 , A61K2039/505 , A61P35/00 , C07K14/5759 , C07K14/705 , C07K14/72 , C07K16/22 , C07K2317/76
摘要： The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
-
公开(公告)号：EP3512515A1
公开(公告)日：2019-07-24
申请号：EP17764845.8
申请日：2017-09-15
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Fondation Imagine , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Centre National de la Recherche Scientifique (CNRS) , Université de Caen Normandie , Centre Hospitalier Régional Universitaire De Caen
IPC分类号： A61K31/4196 , A61K31/497 , A61K31/7088 , A61P35/00
-
7.发明公开METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS 审中-公开VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON BETA-THALASSÄMIEN
公开(公告)号：EP3074007A1
公开(公告)日：2016-10-05
申请号：EP14808905.5
申请日：2014-11-28
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Fondation Imagine , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K31/396 , A61P7/00
CPC分类号： A61K31/4196 , A61K31/397 , A61K31/4245 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K31/55 , G01N33/5073 , G01N2500/02 , G01N2500/10
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.
摘要翻译： 本发明涉及用于治疗β-地中海贫血的方法和药物组合物。 特别地，本发明涉及用于治疗有需要的受试者的β-地中海贫血的方法中的XPO1抑制剂。
-
8.发明公开
公开(公告)号：EP3906415A1
公开(公告)日：2021-11-10
申请号：EP20700002.7
申请日：2020-01-02
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Assistance Publique-Hôpitaux de Paris (APHP) , Fondation Imagine , Université Paris Descartes , Centre National de la Recherche Scientifique (CNRS) , Université Paris-Saclay
发明人： HERMINE, Olivier , ROSSIGNOL, Julien , BELAID-CHOUCAIR, Zakia , FOUQUET, Guillemette , COURONNE, Lucile , DUSSIOT, Michael , RIGNAULT-BRICARD, Rachel , COMAN, Tereza , GUILLEM, Flavia , LEPELLETIER, Yves , RENAND, Amédée , MILPIED, Pierre
IPC分类号： G01N33/574
-
公开(公告)号：EP3074007B1
公开(公告)日：2019-07-03
申请号：EP14808905.5
申请日：2014-11-28
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Fondation Imagine , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K31/396 , A61P7/00
-
10.发明公开
公开(公告)号：EP3154536A1
公开(公告)日：2017-04-19
申请号：EP15731531.8
申请日：2015-06-09
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Descartes , Centre National de la Recherche Scientifique (C.N.R.S.)
发明人： HERMINE, Olivier , ARLET, Jean-Benoit , GUILLEM, Flavia , COURTOIS, Genevève , FONTENAY, Michaela
IPC分类号： A61K31/165 , A61P35/02
CPC分类号： A61K31/422 , A61K31/00 , A61K31/366
摘要： The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
摘要翻译： 本发明提供了设计用于干预该缺陷过程并促进或恢复患有骨髓增生异常综合征的个体的红细胞成熟的方法和药物组合物。 该方法涉及通过防止细胞质中Hsp70的螯合来维持GATA-1的活性。 因此，本发明的目的是通过预防GATA-1的蛋白水解失活来提供恢复或增加患有骨髓增生异常综合征的受试者的红细胞成熟的方法。 在一些实施方案中，通过向受试者施用抑制XPO1核转运蛋白的化合物来实现预防。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.031 秒)
